Trial Profile
A Randomized, Double-Blind, Placebo-Controlled Phase II Study of DAS181 in Patients With Parainfluenza Infection
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 19 Dec 2019
Price :
$35
*
At a glance
- Drugs Oplunofusp (Primary)
- Indications Parainfluenza virus infections; Respiratory tract infections
- Focus Adverse reactions
- 06 Jul 2017 Planned primary completion date changed from 30 Jun 2014 to 27 Feb 2014.
- 29 Sep 2011 New trial record